Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis BioMed Central
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis bmcwomenshealth.biomedcentral.com
Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial Nature.com
Endometriosis (EMs) is a common condition that causes dysmenorrhea, chronic pelvic pain, and infertility, affecting millions of women worldwide. Despite the use of assisted reproductive technology, EMs patients often experience …
Endometriosis affects approximately 10% of premenopausal women, with urinary tract involvement in 1% of cases. Ureteric endometriosis is a rare, typically asymptomatic, cause of obstructive renal failure. We present the …
The uterus is a complex organ that requires precise signaling networks to mediate functions necessary for homeostasis and reproductive processes. The transforming growth factor β (TGFβ) superfamily regulates integral signaling …
Endometriosis, while prevalent, can manifest in extra-pelvic locations with varying degrees of rarity, but reports of multiple extra-pelvic sites within a patient are extremely rare. We report a unique case …
Endometriosis (EMs) is a chronic inflammatory disease characterized by the presence of endometrial tissue in the non-uterine cavity, resulting in dysmenorrhea, pelvic pain, and infertility. Epidemiologic data have suggested the …
Dr Hinchcliff on the Addition of Dostarlimab to Chemotherapy in Advanced/Recurrent Endometrial Cancer OncLive
Potential biomarkers and immune infiltration linking endometriosis with recurrent pregnancy loss based on bioinformatics and machine learning Frontiers